东阳光集团联合青云科技打造医药研发智算新范式

Core Insights - Dongyangguang Group's collaboration with Qingyun Technology on the "R&D Intelligent Manufacturing New Foundation" project has been recognized as a typical practice in the digital transformation of the biopharmaceutical industry [1][3] - The project addresses key challenges in AI research and development, such as dispersed computing resources, complex research environments, and high operational pressure, by establishing a unified computing resource scheduling and management system [1] - The AI computing platform developed allows for a full-process closed loop from user management to algorithm development and model deployment, significantly enhancing resource utilization through GPU resource sharing mechanisms [1] Project Implementation and Results - The project has led to a significant reduction in the drug molecule design cycle from 18 months to 12 months, improving efficiency by 33% [3] - Simulation time for high-performance composite materials has decreased by 40%, and cross-base collaboration efficiency has improved by 60%, with ineffective waiting time for researchers reduced by 87.5% [3] - Annual experimental costs have been reduced by 400 million yuan, and operational management costs have decreased by over 30% [3] Implications for the Industry - This case exemplifies the practical value of "Intelligent Computing + AI" in pharmaceutical research and provides a replicable path for digital transformation in traditional manufacturing enterprises [3] - It highlights the core driving role of new productive forces in achieving high-quality development [3]